Last month, I was sitting in a hotel lobby (actually the Bar) in Amsterdam after attending the International Plasma Protein Conference. I started talking with a fellow attendee who is a Patient Advocate for the rare diseases, Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (don’t lose me, I... Show More
Thanks for your comment Rodney. It is an interesting one. Given the supply shortage I wonder how much Share Shire (now Takeda) could take, even if they have a better drug profile. You are right, It was on 9x PE, but had some chunky debt and a lot of Hemophilia earnings still to lose (a few billion revenue, which is all margin, making the future PE a lot higher). It was cheap though and Takeda certainly agreed with you. Also wonder if the market is looking at more than just global plasma comps for CSL?